Abstract
Background: In patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy has been shown to effectively prevent stent thrombosis and other ischemic cardiovascular events. The frequent occurrence of atrial fibrillation (AF) and concomitant CAD in the same individuals, suggests that clinicians will encounter many patients treated with PCI who will require anticoagulant treatment for the prevention of the thromboembolic complications of AF.
Methods: In this narrative review we provide an overview and update of evidence regarding antiplatelet therapy in patients with AF undergoing PCI.
Results: The combination of dual antiplatelet therapy with anticoagulants may further protect a patient from ischemic complications, at the cost, however, of a several-fold increased bleeding risk. The introduction of novel pharmaceutical agents in both categories implies that there is paucity of data regarding the efficacy and, more importantly, the safety of between-drug combinations.
Conclusion: Careful consideration of the patient’s individual characteristics and assessment of the risk for bleeding and thrombotic events using validated risk prediction tools is of great importance in order to maximize the benefits for each patient, while minimizing the risk for hemorrhage.
Keywords: Atrial fibrillation, percutaneous coronary intervention, antiplatelet thepary.
Current Pharmaceutical Design
Title:Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Volume: 22 Issue: 29
Author(s): Theodoros A. Zografos and Demosthenes G. Katritsis
Affiliation:
Keywords: Atrial fibrillation, percutaneous coronary intervention, antiplatelet thepary.
Abstract: Background: In patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy has been shown to effectively prevent stent thrombosis and other ischemic cardiovascular events. The frequent occurrence of atrial fibrillation (AF) and concomitant CAD in the same individuals, suggests that clinicians will encounter many patients treated with PCI who will require anticoagulant treatment for the prevention of the thromboembolic complications of AF.
Methods: In this narrative review we provide an overview and update of evidence regarding antiplatelet therapy in patients with AF undergoing PCI.
Results: The combination of dual antiplatelet therapy with anticoagulants may further protect a patient from ischemic complications, at the cost, however, of a several-fold increased bleeding risk. The introduction of novel pharmaceutical agents in both categories implies that there is paucity of data regarding the efficacy and, more importantly, the safety of between-drug combinations.
Conclusion: Careful consideration of the patient’s individual characteristics and assessment of the risk for bleeding and thrombotic events using validated risk prediction tools is of great importance in order to maximize the benefits for each patient, while minimizing the risk for hemorrhage.
Export Options
About this article
Cite this article as:
Zografos A. Theodoros and Katritsis G. Demosthenes, Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention, Current Pharmaceutical Design 2016; 22 (29) . https://dx.doi.org/10.2174/1381612822666160623070130
DOI https://dx.doi.org/10.2174/1381612822666160623070130 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia
Recent Patents on DNA & Gene Sequences From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry Recent Developments in the Search for Biomarkers for the Diagnosis and Monitoring of Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Dimensional Assessment of Hypochondriacal Fears and Beliefs
Current Psychiatry Reviews Synthesis and Evaluation of Compounds Containing 4-arylpiperazinyl Moieties Linked to a 2-(pyridin-3-yl)-1H-benzimidazole as p38 MAP Kinase Inhibitors
Letters in Drug Design & Discovery A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer’s Disease
Current Clinical Pharmacology microRNAs in Cardiovascular Disease: Small Molecules but Big Roles
Current Topics in Medicinal Chemistry Dendritic Cells: A Double-Edge Sword in Atherosclerotic Inflammation
Current Pharmaceutical Design Effects of Medroxyprogesterone Acetate on the Risk of Cardiovascular Disease in Postmenopausal Women Receiving Estrogen
Vascular Disease Prevention (Discontinued) Ethical Considerations in Conducting Pediatric and Neonatal Research in Clinical Pharmacology
Current Pharmaceutical Design Understanding The Role of Inflammasome in Angina Pectoris
Current Protein & Peptide Science Mechanisms of the Beneficial Actions of Ischemic Preconditioning on Subcellular Remodeling in Ischemic-Reperfused Heart
Current Cardiology Reviews Phenolics and Terpenoids; the Promising New Search for Anthelmintics: A Critical Review
Mini-Reviews in Medicinal Chemistry Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Dual Modulation of Vascular Function by Perivascular Adipose Tissue and Its Potential Correlation with Adiposity/Lipoatrophy-Related Vascular Dysfunction
Current Pharmaceutical Design Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Aliskiren in Patients with Diabetes: A Systematic Review
Current Vascular Pharmacology